1. Home
  2. FBNC vs WGS Comparison

FBNC vs WGS Comparison

Compare FBNC & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Bancorp

FBNC

First Bancorp

HOLD

Current Price

$55.20

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

Logo GeneDx Holdings Corp.

WGS

GeneDx Holdings Corp.

HOLD

Current Price

$57.52

Market Cap

2.6B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
FBNC
WGS
Founded
1934
2017
Country
United States
United States
Employees
N/A
1300
Industry
Major Banks
Retail: Computer Software & Peripheral Equipment
Sector
Finance
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.6B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
FBNC
WGS
Price
$55.20
$57.52
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$61.25
$140.71
AVG Volume (30 Days)
175.2K
679.7K
Earning Date
04-22-2026
04-29-2026
Dividend Yield
1.73%
N/A
EPS Growth
45.65
N/A
EPS
2.68
N/A
Revenue
$67,623,000.00
N/A
Revenue This Year
$37.82
$29.98
Revenue Next Year
$2.30
$26.04
P/E Ratio
$20.74
$1,251.58
Revenue Growth
N/A
N/A
52 Week Low
$34.50
$55.17
52 Week High
$62.64
$170.87

Technical Indicators

Market Signals
Indicator
FBNC
WGS
Relative Strength Index (RSI) 47.07 27.96
Support Level $52.03 N/A
Resistance Level $56.44 $95.75
Average True Range (ATR) 1.22 4.43
MACD 0.26 -1.25
Stochastic Oscillator 70.67 5.64

Price Performance

Historical Comparison
FBNC
WGS

About FBNC First Bancorp

First Bancorp is a bank holding company. The company is engaged in providing commercial and consumer banking services, mortgage lending, SBA lending, accounts receivable financing, and investment advisory services.

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: